{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T23:25:02Z","timestamp":1787181902575,"version":"build-2736575974"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009687","name":"Wroc\u0142aw Medical University","doi-asserted-by":"publisher","award":["SUBZ.D020.25.046"],"award-info":[{"award-number":["SUBZ.D020.25.046"]}],"id":[{"id":"10.13039\/501100009687","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009687","name":"Wroc\u0142aw Medical University","doi-asserted-by":"publisher","award":["SUBK.D022.22.026"],"award-info":[{"award-number":["SUBK.D022.22.026"]}],"id":[{"id":"10.13039\/501100009687","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.biopha.2026.119799","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T04:07:22Z","timestamp":1785298042000},"page":"119799","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Differential cellular responses of breast cancer and non-tumorigenic mammary epithelial cells to a fullerene-doxorubicin complex"],"prefix":"10.1016","volume":"202","author":[{"given":"Natalia","family":"Zar\u0119ba-Wdowiak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1817-3140","authenticated-orcid":false,"given":"Monika","family":"O\u0142dakowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0635-5737","authenticated-orcid":false,"given":"Magdalena","family":"Wojtas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Kepinska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2026.119799_bib1","doi-asserted-by":"crossref","unstructured":"Erratum to \"Cancer statistics, 2024\". CA Cancer J Clin., 74 (2024), pp. 203. doi: 10.3322\/caac.21830.","DOI":"10.3322\/caac.21830"},{"key":"10.1016\/j.biopha.2026.119799_bib2","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1186\/s12943-024-02165-x","article-title":"Metabolic reprogramming and therapeutic resistance in primary and metastatic breast cancer","volume":"23","author":"Liu","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.biopha.2026.119799_bib3","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3390\/metabo16010060","article-title":"Mitochondrial Redox Vulnerabilities in Triple-Negative Breast Cancer: Integrative Perspectives and Emerging Therapeutic Strategies","volume":"16","author":"Cruz-Gregorio","year":"2026","journal-title":"Metabolites"},{"key":"10.1016\/j.biopha.2026.119799_bib4","doi-asserted-by":"crossref","first-page":"15182","DOI":"10.1073\/pnas.1922072117","article-title":"Uncoupling DNA damage from chromatin damage to detoxify doxorubicin","volume":"117","author":"Qiao","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2026.119799_bib5","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/jphp.12539","article-title":"Increasing role of the cancer chemotherapeutic doxorubicin in cellular metabolism","volume":"68","author":"Meredith","year":"2016","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.biopha.2026.119799_bib6","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13058-024-01799-5","article-title":"Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin\/OKI-179 to promote apoptosis","volume":"26","author":"Smoots","year":"2024","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.biopha.2026.119799_bib7","first-page":"681","article-title":"Doxorubicin-Induced Cardiotoxicity and the Emerging Role of SGLT2 Inhibitors: From Glycemic Control to Cardio-Oncology","volume":"18","author":"Goje","year":"2025","journal-title":"Pharm. (Basel)"},{"key":"10.1016\/j.biopha.2026.119799_bib8","doi-asserted-by":"crossref","DOI":"10.5772\/34692","article-title":"Doxorubicin-Induced Oxidative Injury of Cardiomyocytes - Do We Have Right Strategies for Prevention?","author":"Milic","year":"2012","journal-title":"Cardiotoxicity Oncol. Treat."},{"key":"10.1016\/j.biopha.2026.119799_bib9","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1038\/s41565-019-0567-y","article-title":"Smart cancer nanomedicine","volume":"14","author":"van der Meel","year":"2019","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.biopha.2026.119799_bib10","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1186\/s12967-025-06976-4","article-title":"Targeting mitochondrial transporters and metabolic reprogramming for disease treatment","volume":"23","author":"Anselme","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.biopha.2026.119799_bib11","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41392-025-02311-x","article-title":"Mitochondrial metabolism and cancer therapeutic innovation","volume":"10","author":"Du","year":"2025","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.biopha.2026.119799_bib12","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.cotox.2018.09.001","article-title":"Engineered nanomaterials and oxidative stress: current understanding and future challenges","volume":"13","author":"Mendoza","year":"2019","journal-title":"Curr. Opin. Toxicol."},{"key":"10.1016\/j.biopha.2026.119799_bib13","first-page":"430","article-title":"Advances in Targeted Delivery of Doxorubicin for Cancer Chemotherapy","volume":"12","author":"Xia","year":"2025","journal-title":"Bioeng. (Basel)"},{"key":"10.1016\/j.biopha.2026.119799_bib14","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3390\/pharmaceutics14010102","article-title":"The Impact of Fullerenes as Doxorubicin Nano-Transporters on Metallothionein and Superoxide Dismutase Status in MCF-10A Cells","volume":"14","author":"Zar\u0119ba","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2026.119799_bib15","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41573-021-00233-1","article-title":"Targeting oxidative stress in disease: promise and limitations of antioxidant therapy","volume":"20","author":"Forman","year":"2021","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.biopha.2026.119799_bib16","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.drudis.2019.01.013","article-title":"Fullerene-based delivery systems","volume":"24","author":"Kazemzadeh","year":"2019","journal-title":"Drug. Discov. Today"},{"key":"10.1016\/j.biopha.2026.119799_bib17","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1002\/elps.201800148","article-title":"Fullerene as a doxorubicin nanotransporter for targeted breast cancer therapy: Capillary electrophoresis analysis","volume":"39","author":"Kepinska","year":"2018","journal-title":"Electrophoresis"},{"key":"10.1016\/j.biopha.2026.119799_bib18","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.3390\/ijms19103253","article-title":"Metallothionein and Superoxide Dismutase-Antioxidative Protein Status in Fullerene-Doxorubicin Delivery to MCF-7 Human Breast Cancer Cells","volume":"19","author":"Kepinska","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119799_bib19","doi-asserted-by":"crossref","first-page":"6523","DOI":"10.1039\/C7TB00855D","article-title":"Echegoyen L Fullerenes in biology and medicine","volume":"5","author":"Castro","year":"2017","journal-title":"J. Mater. Chem. B Mater. Biol. Med."},{"key":"10.1016\/j.biopha.2026.119799_bib20","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1002\/adma.201203486","article-title":"What makes fullerene acceptors special as electron acceptors in organic solar cells and how to replace them","volume":"25","author":"Liu","year":"2013","journal-title":"Adv. Mater. Weinh."},{"key":"10.1016\/j.biopha.2026.119799_bib21","doi-asserted-by":"crossref","first-page":"4360","DOI":"10.1021\/es0603655","article-title":"Antibacterial activity of fullerene water suspensions: effects of preparation method and particle size","volume":"40","author":"Lyon","year":"2006","journal-title":"Environ. Sci. Technol."},{"key":"10.1016\/j.biopha.2026.119799_bib22","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1021\/nl051866b","article-title":"60]fullerene is a powerful antioxidant in vivo with no acute or subacute toxicity","volume":"5","author":"Gharbi","year":"2005","journal-title":"Nano Lett."},{"key":"10.1016\/j.biopha.2026.119799_bib23","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.3390\/molecules26113252","article-title":"Antitumor Activity and Potential Mechanism of Novel Fullerene Derivative Nanoparticles","volume":"26","author":"Ye","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.biopha.2026.119799_bib24","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jhazmat.2015.08.046","article-title":"Toxicity of polyhydroxylated fullerene to mitochondria","volume":"301","author":"Yang","year":"2016","journal-title":"J. Hazard. Mater."},{"key":"10.1016\/j.biopha.2026.119799_bib25","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00204-013-1096-3","article-title":"Effects of N-acetyl-l-cysteine on target sites of hydroxylated fullerene-induced cytotoxicity in isolated rat hepatocytes","volume":"88","author":"Nakagawa","year":"2013","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.biopha.2026.119799_bib26","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s00204-011-0688-z","article-title":"Cytotoxic effects of hydroxylated fullerenes on isolated rat hepatocytes via mitochondrial dysfunction","volume":"85","author":"Nakagawa","year":"2011","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.biopha.2026.119799_bib27","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s12964-025-02218-8","article-title":"The ester derivative Palmitoylcarnitine abrogates cervical cancer cell survival by enhancing lipotoxicity and mitochondrial dysfunction","volume":"23","author":"Eswaran","year":"2025","journal-title":"Cell. Commun. Signal."},{"key":"10.1016\/j.biopha.2026.119799_bib28","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41392-025-02141-x","article-title":"Energy metabolism in health and diseases","volume":"10","author":"Liu","year":"2025","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.biopha.2026.119799_bib29","unstructured":"Cancer Today, International Agency for Research on Cancer https:\/\/gco.iarc.who.int\/today\/en\/dataviz\/pie?mode=cancer&group_populations=1&sexes=2&types=0, 2022 (accessed 30 March 2026)."},{"key":"10.1016\/j.biopha.2026.119799_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.fct.2019.110834","article-title":"An update on the mechanisms related to cell death and toxicity of doxorubicin and the protective role of nutrients","volume":"134","author":"Varela-L\u00f3pez","year":"2019","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.biopha.2026.119799_bib31","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","article-title":"Triple-negative breast cancer molecular subtyping and treatment progress","volume":"22","author":"Yin","year":"2020","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.biopha.2026.119799_bib32","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13058-024-01799-5","article-title":"Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin\/OKI-179 to promote apoptosis","volume":"26","author":"Smoots","year":"2024","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.biopha.2026.119799_bib33","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1021\/nn100448z","article-title":"Potent angiogenesis inhibition by the particulate form of fullerene derivatives","volume":"4","author":"Meng","year":"2010","journal-title":"ACS Nano"},{"key":"10.1016\/j.biopha.2026.119799_bib34","first-page":"99","article-title":"Synthesis of amphiphilic amino acid C60 derivatives and their protective effect on hydrogen peroxide-induced apoptosis in rat pheochromocytoma cells","volume":"46","author":"Zhen","year":"2007","journal-title":"Carbon"},{"key":"10.1016\/j.biopha.2026.119799_bib35","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ijpharm.2015.09.016","article-title":"C60-fullerenes for delivery of docetaxel to breast cancer cells: A promising approach for enhanced efficacy and better pharmacokinetic profile","volume":"495","author":"Raza","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biopha.2026.119799_bib36","doi-asserted-by":"crossref","first-page":"4366","DOI":"10.3390\/molecules27144366","article-title":"Novel C60 Fullerenol-Gentamicin Conjugate-Physicochemical Characterization and Evaluation of Antibacterial and Cytotoxic Properties","volume":"27","author":"Nurzynska","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.biopha.2026.119799_bib37","doi-asserted-by":"crossref","first-page":"23164","DOI":"10.1039\/C4CP03367A","article-title":"Characterization of C60 fullerene complexation with antibiotic doxorubicin","volume":"16","author":"Prylutskyy","year":"2014","journal-title":"Phys. Chem. Chem. Phys."},{"key":"10.1016\/j.biopha.2026.119799_bib38","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.3762\/bjnano.8.149","article-title":"A nanocomplex of C60 fullerene with cisplatin: design, characterization and toxicity","volume":"8","author":"Prylutska","year":"2017","journal-title":"Beilstein J. Nanotechnol."},{"key":"10.1016\/j.biopha.2026.119799_bib39","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s40268-014-0074-4","article-title":"C60 fullerene as synergistic agent in tumor-inhibitory Doxorubicin treatment","volume":"14","author":"Prylutska","year":"2014","journal-title":"Drugs R. D."},{"key":"10.1016\/j.biopha.2026.119799_bib40","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/mawe.201300105","article-title":"Photoexcited fullerene C60 disturbs prooxidant-antioxidant balance in leukemic L1210 cells","volume":"44","author":"Grynyuk","year":"2013","journal-title":"Mat. -Wiss. U. Werkst."},{"key":"10.1016\/j.biopha.2026.119799_bib41","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13065-022-00888-w","article-title":"Synthesis, characterization, and cytotoxicity of doxorubicin-loaded polycaprolactone nanocapsules as controlled anti-hepatocellular carcinoma drug release system","volume":"16","author":"Fahmi","year":"2022","journal-title":"BMC Chem."},{"key":"10.1016\/j.biopha.2026.119799_bib42","series-title":"Advances in Nanomedicine for the Delivery of Therapeutic Nucleic Acids","first-page":"165","article-title":"Pharmacokinetics and biodistribution of the nanoparticles","author":"Raza","year":"2017"},{"key":"10.1016\/j.biopha.2026.119799_bib43","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s00204-019-02441-6","article-title":"Toxicity of C60 fullerene\u2013cisplatin nanocomplex against Lewis lung carcinoma cells","volume":"93","author":"Prylutska","year":"2019","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.biopha.2026.119799_bib44","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jhazmat.2015.08.046","article-title":"Toxicity of polyhydroxylated fullerene to mitochondria","volume":"301","author":"Yang","year":"2016","journal-title":"J. Hazard. Mater."},{"key":"10.1016\/j.biopha.2026.119799_bib45","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41392-025-02311-x","article-title":"Mitochondrial metabolism and cancer therapeutic innovation","volume":"10","author":"Du","year":"2025","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.biopha.2026.119799_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2021.167378","article-title":"Apoptosis, Pyroptosis, and Necroptosis-Oh My! The Many Ways a Cell Can Die","volume":"434","author":"Ketelut-Carneiro","year":"2022","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.biopha.2026.119799_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2025.101288","article-title":"Drug resistance in breast cancer: Mechanisms and strategies for management","volume":"83","author":"Wu","year":"2025","journal-title":"Drug. Resist. Updat."},{"key":"10.1016\/j.biopha.2026.119799_bib48","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3389\/fonc.2018.00337","article-title":"Phenotypic Basis for Matrix Stiffness-Dependent Chemoresistance of Breast Cancer Cells to Doxorubicin","volume":"8","author":"Joyce","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biopha.2026.119799_bib49","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41523-019-0108-8","article-title":"Simultaneous defeat of MCF7 and MDA-MB-231 resistances by a hypericin PDT-tamoxifen hybrid therapy","volume":"5","author":"Theodossiou","year":"2019","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.biopha.2026.119799_bib50","doi-asserted-by":"crossref","first-page":"17078","DOI":"10.1038\/cddiscovery.2017.78","article-title":"Parthenolide prevents resistance of MDA-MB231 cells to doxorubicin and mitoxantrone: the role of Nrf2","volume":"3","author":"Carlisi","year":"2017","journal-title":"Cell. Death Discov."},{"key":"10.1016\/j.biopha.2026.119799_bib51","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.4161\/epi.22713","article-title":"Modifying metabolically sensitive histone marks by inhibiting glutamine metabolism affects gene expression and alters cancer cell phenotype","volume":"7","author":"Simpson","year":"2012","journal-title":"Epigenetics"},{"key":"10.1016\/j.biopha.2026.119799_bib52","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1166\/jbn.2015.2058","article-title":"Application of C60 Fullerene-Doxorubicin Complex for Tumor Cell Treatment In Vitro and In Vivo","volume":"11","author":"Panchuk","year":"2015","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.biopha.2026.119799_bib53","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s11671-019-2894-1","article-title":"Complexation with C60 Fullerene Increases Doxorubicin Efficiency against Leukemic Cells In Vitro","volume":"14","author":"Grebinyk","year":"2019","journal-title":"Nanoscale Res. Lett."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226008358?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226008358?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T22:52:26Z","timestamp":1787179946000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226008358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":53,"alternative-id":["S0753332226008358"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119799","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differential cellular responses of breast cancer and non-tumorigenic mammary epithelial cells to a fullerene-doxorubicin complex","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119799","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119799"}}